6IGC image
Deposition Date 2018-09-25
Release Date 2018-11-21
Last Version Date 2023-11-22
Entry Detail
PDB ID:
6IGC
Title:
Crystal structure of HPV58/33/52 chimeric L1 pentamer
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.50 Å
R-Value Free:
0.34
R-Value Work:
0.31
R-Value Observed:
0.31
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Major capsid protein L1
Gene (Uniprot):L1
Mutations:S80N, N82T, N84A, V87L, C202S, T375K, G378S, D383E
Chain IDs:A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z, AA (auth: a), BA (auth: b), CA (auth: c), DA (auth: d), EA (auth: e), FA (auth: f), GA (auth: g), HA (auth: h), IA (auth: i), JA (auth: j), KA (auth: k), LA (auth: l), MA (auth: m), NA (auth: n)
Chain Length:524
Number of Molecules:40
Biological Source:Human papillomavirus type 58
Ligand Molecules
Primary Citation
Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
Nat Commun 9 5360 5360 (2018)
PMID: 30560935 DOI: 10.1038/s41467-018-07199-6

Abstact

Sequence variability in surface-antigenic sites of pathogenic proteins is an important obstacle in vaccine development. Over 200 distinct genomic sequences have been identified for human papillomavirus (HPV), of which more than 18 are associated with cervical cancer. Here, based on the high structural similarity of L1 surface loops within a group of phylogenetically close HPV types, we design a triple-type chimera of HPV33/58/52 using loop swapping. The chimeric VLPs elicit neutralization titers comparable with a mix of the three wild-type VLPs both in mice and non-human primates. This engineered region of the chimeric protein recapitulates the conformational contours of the antigenic surfaces of the parental-type proteins, offering a basis for this high immunity. Our stratagem is equally successful in developing other triplet-type chimeras (HPV16/35/31, HPV56/66/53, HPV39/68/70, HPV18/45/59), paving the way for the development of an improved HPV prophylactic vaccine against all carcinogenic HPV strains. This technique may also be extrapolated to other microbes.

Legend

Protein

Chemical

Disease

Primary Citation of related structures